ARS Pharmaceuticals (SPRY) Times Interest Earned (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Times Interest Earned of -$1.69 for Q1 2026, up 91.09% sequentially from -$18.98 in Q4 2025, and up 99.95% YoY from -$0.85 in Q1 2025.
ARS Pharmaceuticals (SPRY) Times Interest Earned (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Times Interest Earned for 7 years, with the latest figure at -$1.69 in Q1 2026.
- Quarterly Times Interest Earned rose 99.95% year-over-year to -$1.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.69 (up 99.77% YoY) and the FY2025 annual result came in at -$2.3, down 5224.51% from the prior year.
- Times Interest Earned climbed to -$1.69 in Q1 2026 per SPRY's latest filing, from -$18.98 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.0 in Q1 2023 and troughed at -$3379.7 in Q1 2025.
- A 5-year average of -$238.52 and a median of -$0.83 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned surged 99.97% in 2023, then plunged 1986412.08% in 2025.
- Over 5 years, Times Interest Earned stood at -$154.43 in 2022, then jumped by 100.0% to -$0.0 in 2023, then slumped by 22032750.92% to -$256.51 in 2024, then surged by 92.6% to -$18.98 in 2025, then soared by 91.09% to -$1.69 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$1.69, -$18.98, and -$0.89 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -1.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.75 |
| Mar 31, 2026 | -1.69 |
| Dec 31, 2025 | -18.98 |
| Sep 30, 2025 | -0.89 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | -3,379.73 |
| Dec 31, 2024 | -256.51 |
| Sep 30, 2024 | -0.16 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.17 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | -154.43 |
| Sep 30, 2022 | -0.78 |
| Jun 30, 2022 | -0.88 |
| Mar 31, 2022 | -1.58 |
| Dec 31, 2021 | -87.47 |
| Sep 30, 2021 | -1.04 |
| Jun 30, 2021 | -0.20 |